newsfilter
← Latest News
GlobeNewswire·

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN –